

Emily De Los Reyes

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2933086/publications.pdf>

Version: 2024-02-01

18
papers

571
citations

1163117

8
h-index

940533

16
g-index

20
all docs

20
docs citations

20
times ranked

760
citing authors

#	ARTICLE	IF	CITATIONS
1	La Crosse Virus Neuroinvasive Disease in Children: A Contemporary Analysis of Clinical/Neurobehavioral Outcomes and Predictors of Disease Severity. <i>Clinical Infectious Diseases</i> , 2023, 76, e1114-e1122.	5.8	4
2	Biallelic SEPSECS variants in two siblings with pontocerebellar hypoplasia type 2D underscore the relevance of splice-disrupting synonymous variants in disease.. <i>Journal of Physical Education and Sports Management</i> , 2022, , mcs.a006165.	1.2	0
3	Inherited and de novo variants extend the etiology of TAOK1-associated neurodevelopmental disorder. <i>Journal of Physical Education and Sports Management</i> , 2022, , mcs.a006180.	1.2	6
4	Clinical Pharmacokinetics and Pharmacodynamics of Cerliponase Alfa, Enzyme Replacement Therapy for CLN2 Disease by Intracerebroventricular Administration. <i>Clinical and Translational Science</i> , 2021, 14, 635-644.	3.1	4
5	Risperidone or Aripiprazole Can Resolve Autism Core Signs and Symptoms in Young Children: Case Study. <i>Children</i> , 2021, 8, 318.	1.5	9
6	Precision Medicine in the 21st Century: The Personalized Approach to Rare Neurologic Disease. <i>Seminars in Pediatric Neurology</i> , 2021, 37, 100883.	2.0	1
7	Management of CLN1 Disease: International Clinical Consensus. <i>Pediatric Neurology</i> , 2021, 120, 38-51.	2.1	10
8	Cerliponase Alfa for the Treatment of Atypical Phenotypes of CLN2 Disease: A Retrospective Case Series. <i>Journal of Child Neurology</i> , 2021, 36, 468-474.	1.4	10
9	<p>Pharmacological Intervention in Children with Autism Spectrum Disorder with Standard Supportive Therapies Significantly Improves Core Signs and Symptoms: A Single-Center, Retrospective Case Series</p>. <i>Neuropsychiatric Disease and Treatment</i> , 2020, Volume 16, 2779-2794.	2.2	9
10	Current knowledge of SLC6A1-related neurodevelopmental disorders. <i>Brain Communications</i> , 2020, 2, fcaa170.	3.3	44
11	Intracerebroventricular Cerliponase Alfa for Neuronal Ceroid Lipofuscinosis Type 2 Disease: Clinical Practice Considerations From US Clinics. <i>Pediatric Neurology</i> , 2020, 110, 64-70.	2.1	12
12	Batten disease and perioperative complications: a retrospective descriptive study. <i>Journal of Anesthesia</i> , 2020, 34, 342-347.	1.7	2
13	Study of Intraventricular Cerliponase Alfa for CLN2 Disease. <i>New England Journal of Medicine</i> , 2018, 378, 1898-1907.	27.0	348
14	Low-level expression of EPG5 leads to an attenuated Vici syndrome phenotype. <i>American Journal of Medical Genetics, Part A</i> , 2018, 176, 1207-1211.	1.2	9
15	Management Strategies for CLN2 Disease. <i>Pediatric Neurology</i> , 2017, 69, 102-112.	2.1	80
16	Neuronal Ceroid Lipofuscinosis and Associated Sleep Abnormalities. <i>Pediatric Neurology</i> , 2016, 59, 30-35.	2.1	10
17	Neurologic complications of congenital heart disease and its treatment. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2014, 119, 49-59.	1.8	10
18	NEURODEVELOPMENTAL DISORDERS. , 2012, , 81-86.		3